J. Safra Sarasin Holding AG Increases Stock Position in Hologic, Inc. $HOLX

J. Safra Sarasin Holding AG increased its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 109.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 25,724 shares of the medical equipment provider’s stock after buying an additional 13,444 shares during the period. J. Safra Sarasin Holding AG’s holdings in Hologic were worth $1,736,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company lifted its stake in shares of Hologic by 294.3% in the second quarter. The Manufacturers Life Insurance Company now owns 11,022,455 shares of the medical equipment provider’s stock worth $718,223,000 after acquiring an additional 8,227,318 shares in the last quarter. Invesco Ltd. increased its holdings in Hologic by 72.5% during the 2nd quarter. Invesco Ltd. now owns 8,340,785 shares of the medical equipment provider’s stock worth $543,486,000 after purchasing an additional 3,505,828 shares during the last quarter. Norges Bank acquired a new position in shares of Hologic in the 2nd quarter valued at approximately $180,055,000. Allspring Global Investments Holdings LLC raised its position in shares of Hologic by 473.5% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 1,701,820 shares of the medical equipment provider’s stock valued at $111,180,000 after purchasing an additional 1,405,085 shares in the last quarter. Finally, Black Creek Investment Management Inc. boosted its stake in shares of Hologic by 26.1% during the 2nd quarter. Black Creek Investment Management Inc. now owns 4,027,829 shares of the medical equipment provider’s stock valued at $262,453,000 after buying an additional 832,444 shares during the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Stock Performance

Shares of NASDAQ HOLX opened at $75.20 on Wednesday. The company has a quick ratio of 3.06, a current ratio of 3.75 and a debt-to-equity ratio of 0.50. The firm’s 50-day moving average price is $74.84 and its two-hundred day moving average price is $70.72. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $75.36. The stock has a market capitalization of $16.79 billion, a P/E ratio of 30.32, a P/E/G ratio of 2.13 and a beta of 0.69.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 earnings per share for the quarter, topping analysts’ consensus estimates of $1.10 by $0.03. Hologic had a return on equity of 20.13% and a net margin of 13.80%.The business had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $1.03 billion. During the same period in the prior year, the firm earned $1.01 EPS. The business’s quarterly revenue was up 6.2% on a year-over-year basis. As a group, sell-side analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Analyst Upgrades and Downgrades

HOLX has been the topic of several recent analyst reports. Raymond James Financial cut shares of Hologic from a “moderate buy” rating to a “hold” rating in a report on Wednesday, October 22nd. Evercore ISI downgraded shares of Hologic from an “outperform” rating to an “in-line” rating and dropped their target price for the stock from $79.00 to $78.00 in a research report on Monday, January 5th. BNP Paribas Exane lowered shares of Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 target price on the stock. in a research note on Friday, November 21st. Leerink Partners lifted their price target on Hologic from $70.00 to $78.00 and gave the stock a “market perform” rating in a research note on Tuesday, October 21st. Finally, Mizuho lowered Hologic from an “outperform” rating to a “neutral” rating and boosted their price objective for the company from $70.00 to $78.00 in a report on Thursday, October 23rd. Three equities research analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $79.31.

Hologic Company Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.